|
US4777127A
(en)
|
1985-09-30 |
1988-10-11 |
Labsystems Oy |
Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
|
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
|
US4704692A
(en)
|
1986-09-02 |
1987-11-03 |
Ladner Robert C |
Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
GB8702816D0
(en)
|
1987-02-07 |
1987-03-11 |
Al Sumidaie A M K |
Obtaining retrovirus-containing fraction
|
|
US5219740A
(en)
|
1987-02-13 |
1993-06-15 |
Fred Hutchinson Cancer Research Center |
Retroviral gene transfer into diploid fibroblasts for gene therapy
|
|
AP129A
(en)
|
1988-06-03 |
1991-04-17 |
Smithkline Biologicals S A |
Expression of retrovirus gag protein eukaryotic cells
|
|
EP0832980B1
(en)
|
1989-01-23 |
2002-06-19 |
Chiron Corporation |
Recombinant therapies for infection and hyperproliferative disorders
|
|
EP1001032A3
(en)
|
1989-08-18 |
2005-02-23 |
Chiron Corporation |
Recombinant retroviruses delivering vector constructs to target cells
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
US5283173A
(en)
|
1990-01-24 |
1994-02-01 |
The Research Foundation Of State University Of New York |
System to detect protein-protein interactions
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
ATE237694T1
(de)
|
1991-08-20 |
2003-05-15 |
Us Gov Health & Human Serv |
Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
|
|
ES2136092T3
(es)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
Procedimientos para la produccion de anticuerpos humanizados.
|
|
WO1993010218A1
(en)
|
1991-11-14 |
1993-05-27 |
The United States Government As Represented By The Secretary Of The Department Of Health And Human Services |
Vectors including foreign genes and negative selective markers
|
|
GB9125623D0
(en)
|
1991-12-02 |
1992-01-29 |
Dynal As |
Cell modification
|
|
FR2688514A1
(fr)
|
1992-03-16 |
1993-09-17 |
Centre Nat Rech Scient |
Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
|
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
|
EP0650370A4
(en)
|
1992-06-08 |
1995-11-22 |
Univ California |
METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
|
|
EP0644946A4
(en)
|
1992-06-10 |
1997-03-12 |
Us Health |
VECTOR PARTICLES RESISTANT TO INACTIVATION BY HUMAN SERUM.
|
|
GB2269175A
(en)
|
1992-07-31 |
1994-02-02 |
Imperial College |
Retroviral vectors
|
|
EP0673431A1
(en)
|
1992-12-03 |
1995-09-27 |
Genzyme Corporation |
Gene therapy for cystic fibrosis
|
|
EP0705344B8
(en)
|
1993-06-24 |
2006-05-10 |
Advec Inc. |
Adenovirus vectors for gene therapy
|
|
EP0648835A1
(en)
|
1993-10-14 |
1995-04-19 |
The Procter & Gamble Company |
Use of alkaline polyammonium salts to increase cationic density in fabric softeners
|
|
DE69435223D1
(de)
|
1993-10-25 |
2009-09-03 |
Canji Inc |
Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
|
|
US6265150B1
(en)
|
1995-06-07 |
2001-07-24 |
Becton Dickinson & Company |
Phage antibodies
|
|
US5756910A
(en)
|
1996-08-28 |
1998-05-26 |
Burgett, Inc. |
Method and apparatus for actuating solenoids in a player piano
|
|
EP0968284B1
(en)
|
1996-11-20 |
2006-12-13 |
Introgen Therapeutics, Inc. |
An improved method for the production and purification of adenoviral vectors
|
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
|
CN101903403B
(zh)
|
2007-10-19 |
2016-03-16 |
西雅图基因公司 |
Cd19结合剂及其应用
|
|
JPWO2010110346A1
(ja)
|
2009-03-24 |
2012-10-04 |
独立行政法人理化学研究所 |
白血病幹細胞マーカー
|
|
JP6073135B2
(ja)
|
2009-10-19 |
2017-02-01 |
トライステム・トレイディング・(キプロス)・リミテッドTriStem Trading (Cyprus) Limited |
再プログラム化成熟成体細胞を用いる治療
|
|
EP2580243B1
(en)
|
2010-06-09 |
2019-10-16 |
Genmab A/S |
Antibodies against human cd38
|
|
CA2805442C
(en)
|
2010-07-21 |
2020-05-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of an hla locus
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
US9409950B2
(en)
|
2010-12-23 |
2016-08-09 |
Biogen Ma Inc. |
Linker peptides and polypeptides comprising same
|
|
US20130309223A1
(en)
|
2012-05-18 |
2013-11-21 |
Seattle Genetics, Inc. |
CD33 Antibodies And Use Of Same To Treat Cancer
|
|
ES2728782T3
(es)
|
2012-05-25 |
2019-10-28 |
Univ California |
Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
|
|
WO2014093694A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
JP6608807B2
(ja)
|
2013-05-29 |
2019-11-20 |
セレクティス |
Rnaガイドcasヌクレアーゼ系を用いることによって免疫療法のためにt細胞を操作するための方法
|
|
US10189899B2
(en)
|
2013-07-23 |
2019-01-29 |
Biocon Limited |
Use of a CD6 binding partner and method based thereon
|
|
EP2833591A1
(en)
|
2013-07-31 |
2015-02-04 |
Siemens Aktiengesellschaft |
Subsea data communication interface unit
|
|
WO2015048577A2
(en)
|
2013-09-27 |
2015-04-02 |
Editas Medicine, Inc. |
Crispr-related methods and compositions
|
|
WO2015090229A1
(en)
|
2013-12-20 |
2015-06-25 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
DK3105317T3
(en)
|
2014-02-14 |
2019-01-14 |
Cellectis |
Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells
|
|
TR201910814T4
(tr)
|
2014-03-19 |
2019-08-21 |
Cellectis |
Kanser immünoterapisi için cd123 spesifik kimerik antijen reseptörleri.
|
|
ES2765710T3
(es)
|
2014-04-03 |
2020-06-10 |
Cellectis |
Receptores de antígeno quimérico específicos de CD33 para la inmunoterapia del cáncer
|
|
EP3129485B2
(en)
|
2014-04-09 |
2022-12-21 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating cystic fibrosis
|
|
KR20160145186A
(ko)
|
2014-04-24 |
2016-12-19 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
입양 세포 요법 생성물을 생성하기 위한 유도 만능 줄기 세포의 응용
|
|
WO2015195547A1
(en)
|
2014-06-16 |
2015-12-23 |
University Of Washington |
Methods for controlling stem cell potential and for gene editing in stem cells
|
|
US9212225B1
(en)
|
2014-07-01 |
2015-12-15 |
Amphivena Therapeutics, Inc. |
Bispecific CD33 and CD3 binding proteins
|
|
BR112017000939A2
(pt)
|
2014-07-21 |
2017-11-14 |
Novartis Ag |
tratamento de câncer usando um receptor antigênico quimérico de cll-1
|
|
JP6831777B2
(ja)
|
2014-07-21 |
2021-02-17 |
ノバルティス アーゲー |
Cd33キメラ抗原受容体を使用する癌の処置
|
|
CN113699113A
(zh)
|
2014-09-16 |
2021-11-26 |
桑格摩治疗股份有限公司 |
用于造血干细胞中核酸酶介导的基因组工程化和校正的方法和组合物
|
|
KR101799975B1
(ko)
|
2014-10-31 |
2017-11-21 |
에스케이씨하이테크앤마케팅(유) |
액정표시장치용 색순도 향상 및 휘도 보상 필름 및 이를 포함하는 액정표시장치
|
|
US10201606B2
(en)
|
2014-11-26 |
2019-02-12 |
Miltenyi Biotec Gmbh |
Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
|
|
CA2969619A1
(en)
|
2014-12-03 |
2016-06-09 |
Agilent Technologies, Inc. |
Guide rna with chemical modifications
|
|
PE20171094A1
(es)
|
2014-12-04 |
2017-08-07 |
Janssen Biotech Inc |
Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
|
|
US11459390B2
(en)
|
2015-01-16 |
2022-10-04 |
Novartis Ag |
Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
|
|
EP3250602A1
(en)
|
2015-01-26 |
2017-12-06 |
Cellectis |
T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
|
|
CN107787367B
(zh)
*
|
2015-04-06 |
2021-10-26 |
里兰斯坦福初级大学理事会 |
用于crispr/cas介导的基因调控的化学修饰的引导rna
|
|
PL3280729T3
(pl)
*
|
2015-04-08 |
2022-08-22 |
Novartis Ag |
Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
|
|
AU2016251687C1
(en)
|
2015-04-22 |
2023-07-27 |
CureVac SE |
RNA containing composition for treatment of tumor diseases
|
|
GB201507119D0
(en)
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic Acid Construct
|
|
EP3288569A4
(en)
|
2015-04-29 |
2018-12-19 |
Fred Hutchinson Cancer Research Center |
Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
|
|
CA2986310A1
(en)
|
2015-05-11 |
2016-11-17 |
Editas Medicine, Inc. |
Optimized crispr/cas9 systems and methods for gene editing in stem cells
|
|
US11911415B2
(en)
|
2015-06-09 |
2024-02-27 |
Editas Medicine, Inc. |
CRISPR/Cas-related methods and compositions for improving transplantation
|
|
TW201718647A
(zh)
|
2015-06-16 |
2017-06-01 |
建南德克公司 |
抗-cll-1抗體及使用方法
|
|
CA2994746A1
(en)
|
2015-08-11 |
2017-02-16 |
Cellectis |
Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
|
|
WO2017053729A1
(en)
|
2015-09-25 |
2017-03-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Nuclease-mediated genome editing of primary cells and enrichment thereof
|
|
IL258491B2
(en)
|
2015-10-16 |
2023-09-01 |
Univ Columbia |
Preparations and methods for inhibiting antigens of a particular lineage
|
|
WO2017070632A2
(en)
|
2015-10-23 |
2017-04-27 |
President And Fellows Of Harvard College |
Nucleobase editors and uses thereof
|
|
EP3370741B1
(en)
|
2015-11-04 |
2025-10-08 |
The Trustees of the University of Pennsylvania |
Methods and compositions for gene editing in hematopoietic stem cells
|
|
WO2017091615A1
(en)
|
2015-11-24 |
2017-06-01 |
Cellerant Therapeutics, Inc. |
Humanized anti-cll-1 antibodies
|
|
CA3009308A1
(en)
|
2015-12-23 |
2017-06-29 |
Chad Albert COWAN |
Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
|
|
US20190112380A1
(en)
|
2016-03-29 |
2019-04-18 |
University Of Southern California |
Chimeric antigen receptors targeting cancer
|
|
EP3439700A4
(en)
|
2016-04-06 |
2020-01-01 |
University of Florida Research Foundation, Inc. |
BIOMARKER FOR ANTILEUCEMIC THERAPY
|
|
EP3448995A1
(en)
|
2016-04-25 |
2019-03-06 |
Universität Basel |
Allele editing and applications thereof
|
|
CN118652336A
(zh)
|
2016-06-08 |
2024-09-17 |
普瑞赛格恩公司 |
Cd33特异性嵌合抗原受体
|
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
|
CN109562126A
(zh)
|
2016-06-24 |
2019-04-02 |
美商生物细胞基因治疗有限公司 |
嵌合抗原受体(car)、组合物及其使用方法
|
|
US11466291B2
(en)
|
2016-07-06 |
2022-10-11 |
Cellectis |
Sequential gene editing in primary immune cells
|
|
SMT202100555T1
(it)
|
2016-10-21 |
2021-11-12 |
Inst Nat Sante Rech Med |
Metodi per promuovere la risposta di cellule t
|
|
US20190365806A1
(en)
|
2016-11-02 |
2019-12-05 |
Universität Basel |
Immunologically discernible cell surface variants for use in cell therapy
|
|
CN110249052B
(zh)
|
2016-12-30 |
2024-04-12 |
爱迪塔斯医药公司 |
合成的指导分子、组合物和与其相关的方法
|
|
AU2018224387B2
(en)
|
2017-02-22 |
2024-08-08 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing
|
|
KR102709603B1
(ko)
|
2017-02-28 |
2024-09-27 |
보르 바이오파마 인크. |
계통 특이적 단백질의 억제를 위한 조성물 및 방법
|
|
CN110914310A
(zh)
|
2017-03-10 |
2020-03-24 |
哈佛大学的校长及成员们 |
胞嘧啶至鸟嘌呤碱基编辑器
|
|
IL306092A
(en)
|
2017-03-23 |
2023-11-01 |
Harvard College |
Nucleic base editors that include nucleic acid programmable DNA binding proteins
|
|
KR20190140943A
(ko)
|
2017-04-24 |
2019-12-20 |
메모리얼 슬로안 케터링 캔서 센터 |
항-cd33 항체 제제
|
|
CA3064000A1
(en)
|
2017-05-24 |
2018-11-29 |
Effector Therapeutics, Inc. |
Methods and compositions for cellular immunotherapy
|
|
EP3676372A4
(en)
|
2017-08-28 |
2021-06-02 |
The Trustees of Columbia University in the City of New York |
CD33 EXON 2 DEFICIENT DONOR STEM CELLS FOR USE WITH AGENTS AGAINST CD33
|
|
US12359223B2
(en)
|
2018-01-30 |
2025-07-15 |
Editas Medicine, Inc. |
Systems and methods for modulating chromosomal rearrangements
|
|
CN111699254A
(zh)
|
2018-02-08 |
2020-09-22 |
齐默尔根公司 |
使用crispr在棒状杆菌属中进行基因组编辑
|
|
TWI669677B
(zh)
|
2018-03-07 |
2019-08-21 |
光陽工業股份有限公司 |
充電座管理方法、用於充電座管理方法的伺服器及充電座
|
|
AU2019243315A1
(en)
|
2018-03-29 |
2020-09-24 |
Fate Therapeutics, Inc. |
Engineered immune effector cells and use thereof
|
|
WO2020028533A1
(en)
|
2018-08-01 |
2020-02-06 |
Yale University |
Compositions and methods for identification of membrane targets for enhancement of t cell activity against cancer
|
|
CA3110837A1
(en)
|
2018-08-28 |
2020-03-05 |
Vor Biopharma Inc. |
Genetically engineered hematopoietic stem cells and uses thereof
|
|
SG11202103832SA
(en)
|
2018-11-07 |
2021-05-28 |
Crispr Therapeutics Ag |
Anti-cd33 immune cell cancer therapy
|
|
KR20210116526A
(ko)
|
2019-01-16 |
2021-09-27 |
빔 테라퓨틱스, 인크. |
증진된 항-신생물 활성 및 면역억제 내성을 갖는 변형된 면역 세포
|
|
JP7784707B2
(ja)
|
2019-01-16 |
2025-12-12 |
ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク |
系統特異的抗原の阻害のための組成物および方法
|
|
US12600971B2
(en)
|
2019-02-13 |
2026-04-14 |
Beam Therapeutics Inc. |
Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
|
|
AU2020280103A1
(en)
*
|
2019-05-23 |
2021-12-23 |
Vor Biopharma Inc. |
Compositions and methods for CD33 modification
|
|
EA202191979A1
(ru)
|
2019-05-24 |
2021-11-01 |
Зе Трастис Оф Коламбия Юниверсити Ин Зе Сити Оф Нью-Йорк |
Композиции и способы ингибирования линиеспецифических антигенов
|
|
CA3144356A1
(en)
|
2019-06-21 |
2020-12-24 |
Function Oncology, Inc. |
A genetic pharmacopeia for comprehensive functional profiling of human cancers
|
|
AU2020338011A1
(en)
|
2019-08-28 |
2022-03-10 |
Vor Biopharma Inc. |
Compositions and methods for CLL1 modification
|
|
WO2021041977A1
(en)
|
2019-08-28 |
2021-03-04 |
Vor Biopharma, Inc. |
Compositions and methods for cd123 modification
|
|
EP4204564A1
(en)
|
2020-08-28 |
2023-07-05 |
Vor Biopharma Inc. |
Compositions and methods for cd123 modification
|
|
EP4204565A1
(en)
|
2020-08-28 |
2023-07-05 |
Vor Biopharma Inc. |
Compositions and methods for cll1 modification
|
|
WO2022056489A1
(en)
|
2020-09-14 |
2022-03-17 |
Vor Biopharma, Inc. |
Compositions and methods for cd38 modification
|
|
WO2022067240A1
(en)
|
2020-09-28 |
2022-03-31 |
Vor Biopharma, Inc. |
Compositions and methods for cd6 modification
|
|
AU2021413252A1
(en)
*
|
2020-12-31 |
2023-06-08 |
Vor Biopharma Inc. |
Compositions and methods for cd34 gene modification
|
|
EP4381062A1
(en)
|
2021-08-02 |
2024-06-12 |
Vor Biopharma Inc. |
Compositions and methods for gene modification
|
|
US20240408234A1
(en)
*
|
2021-09-14 |
2024-12-12 |
Vor Biopharma Inc. |
Compositions and methods for multiplex base editing in hematopoietic cells
|
|
EP4433512A4
(en)
|
2021-11-19 |
2025-12-31 |
Univ Pennsylvania |
Genetically modified pan-leukocyte-specific CD45 antigen to facilitate T-lymphocyte therapy
|
|
CA3240875A1
(en)
|
2021-12-23 |
2023-06-29 |
Stefanie Urlinger |
Discernible cell surface protein variants of cd45 for use in cell therapy
|
|
JP2025508721A
(ja)
|
2022-02-18 |
2025-04-10 |
ダナ-ファーバー キャンサー インスティテュート, インコーポレイテッド |
細胞表面受容体のエピトープ操作
|